35 filings
8-K
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
8-K
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
8-K
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
TRML
Tourmaline Bio Inc
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
TRML
Tourmaline Bio Inc
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
4pkd7ecg4or753tcbfc1
30 Nov 23
Departure of Directors or Certain Officers
8:25am
8-K
81m hjloem
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
r4jf3vrc09v
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
n2qaabam
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
fh7 gxgxtr
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
8-K/A
0qspgiy7jh8l7u
10 Oct 23
Other Events
4:30pm
8-K
9topd8kda3855p9
6 Oct 23
Talaris Therapeutics Declares Special Dividend
5:30pm
8-K
vh9xn c7aj7ecewa
6 Oct 23
Other Events
5:26pm
8-K
ck1j90imkwmvqj7y7 z9
26 Sep 23
Regulation FD Disclosure
8:21am
8-K
s8c2vxyehj
13 Sep 23
Regulation FD Disclosure
9:13am
8-K
shvw6p8 t0x
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
8-K
iiylog8g
14 Jun 23
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
kprp 61f74c
30 May 23
Talaris Therapeutics Announces Leadership Transition
4:51pm
8-K
srhgbs79 63o5e623fbw
14 Apr 23
Cost Associated with Exit or Disposal Activities
5:20pm
8-K
w9lawt jxn5w
10 Mar 23
Regulation FD Disclosure
4:03pm